Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 13, keine Gesamtzahl für „section“
Suchtreffer
Begriffe & Kennungen
Beyfortus · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenBeyfortus · 4.5 · Nirsevimab should not be mixed with any vaccine in the same syringe or vial (see section 6.2). When administer
Eintrag öffnenBeyonttra · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenBiktarvy · 4.3 · Co-administration with rifampicin and St. John’s wort (Hypericum perforatum) (see section 4.5).
Eintrag öffnenBiktarvy · 4.3 · Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Eintrag öffnenBimervax · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenBimervax · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenBimervax · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenBimervax · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenBimzelx · 4.3 · Clinically important active infections (e.g. active tuberculosis, see section 4.4).
Eintrag öffnenBimzelx · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenBimzelx · 4.5 · Live vaccines should not be given concurrently with bimekizumab (see section 4.4).
Eintrag öffnenBinocrit · 4.3 · - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenBlincyto · 4.3 · - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. - Breast-feeding
Eintrag öffnenBlincyto · 4.8 · For clinical management of CRS, see section 4.4.
Eintrag öffnenBlincyto · 4.8 · For clinical management of elevated liver enzymes, see section 4.4.
Eintrag öffnenBlincyto · 4.8 · For clinical management of infections, see section 4.4.
Eintrag öffnenBlincyto · 4.8 · For clinical management of neurologic events and ICANS, see section 4.2.
Eintrag öffnenBlincyto · 4.8 · The adverse reactions described in this section were identified in clinical studies of patients with B-cell pr
Eintrag öffnenBondronat · 4.3 · - Hypersensitivity to ibandronic acid or to any of the excipients listed in section 6.1. - Hypocalcaemia - Abn
Eintrag öffnen